Related Experiment Video

Updated: Mar 5, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K

The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we

Ahmed Selim1, Ronald Zolty1, Yiannis S Chatzizisis1

  • 1Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

Pharmacology & Therapeutics
|March 25, 2017
PubMed

Insights

This review details recent advances in heart failure with reduced ejection fraction (HFrEF) pharmacotherapy, exploring current treatments and future therapeutic targets to improve patient survival and quality of life.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Cardiovascular diseases are a major global health burden, with heart failure being a common endpoint.
  • Heart failure with reduced ejection fraction (HFrEF) has seen significant therapeutic advancements over the past three decades.
  • Despite progress, there remains a need for improved treatments to enhance survival and quality of life for HFrEF patients.

Purpose of the Study:

  • To review the recent evolution of pharmacotherapy for heart failure with reduced ejection fraction (HFrEF).
  • To examine ongoing clinical trials for novel HFrEF drug therapies.
  • To explore potential future treatment targets and pathways for HFrEF.

Main Methods:

  • Literature review of recent pharmacotherapy advancements in HFrEF.
  • Analysis of ongoing clinical trials for new HFrEF medications.
  • Exploration of emerging therapeutic targets and pathways in HFrEF research.

Main Results:

  • Significant progress has been made in HFrEF pharmacotherapy, particularly in improving survival and quality of life.
  • Several new drug classes and therapeutic strategies are under investigation in ongoing clinical trials.
  • Identification of novel molecular targets and pathways holds promise for future HFrEF treatments.

Conclusions:

  • Recent pharmacotherapy has substantially improved outcomes for HFrEF patients.
  • Ongoing research and clinical trials are crucial for developing next-generation HFrEF treatments.
  • Future therapeutic strategies may involve targeting novel pathways to further optimize HFrEF management.

Keywords:
Heart failureNovel drugsPharmacotherapyReduced ejection fraction

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
439
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
486
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
496